喀什男科好的专科医院喀什怀孕多久能查的出来,喀什妇科医院24在线咨询,喀什处女膜修复手术的妇科医院,喀什尿道炎的危害,华康妇科妇科医院在线QQ,喀什那儿医院男科比较好,喀什治妇科医院有哪些正规

The Senate voted to send Brett Kavanaugh to the Supreme Court on Saturday, ushering in a generational conservative majority and delivering a huge victory to President Donald Trump after a vicious confirmation battle inflamed by allegations of sexual assault against the nominee.As shrieks of "shame, shame, shame" echoed from the public galleries, divided and angry senators voted 50-48 to endorse a lifetime seat on the court for Kavanaugh. The protests underscored the vital importance of an appointment that will have sweeping consequences for some of the nation's most contested disputes over abortion, LGBT rights, the scope of presidential power and the role of religion in society.Hours later, Kavanaugh was sworn in at a private ceremony. Chief Justice John Roberts administered the constitutional oath and retired Supreme Court Justice Anthony Kennedy administered the judicial oath, according to the Supreme Court.The bitter fight over Kavanaugh now moves into the epicenter of the campaign for the midterm elections in November. Republicans are convinced it will motivate their sleepy base. Democrats believe a backlash against the GOP from women voters could help deliver the House of Representatives. And the nature of the fight over Kavanaugh will trigger recriminations inside the Senate and political reverberations outside for years to come.In the end, Republicans were able to use their stranglehold on Capitol Hill and the White House to muscle through the confirmation in a power play that reflected the momentous importance of Trump's 2016 election victory over Hillary Clinton.Still, it was a close-run thing: Kavanaugh's nomination was nearly derailed by Christine Blasey Ford's allegations that the judge assaulted her when they were teenagers in the 1980s, which sparked uproar and forced Republicans to delay the confirmation vote for a week to allow time for a supplemental FBI background check.Trump's first exuberant response to the vote came in a tweet as he flew to Topeka, Kansas for a campaign rally that is likely to become a raucous victory lap."I applaud and congratulate the U.S. Senate for confirming our GREAT NOMINEE, Judge Brett Kavanaugh, to the United States Supreme Court. Later today, I will sign his Commission of Appointment, and he will be officially sworn in. Very exciting!Kavanaugh will be sworn in as an associate justice of the Supreme Court on Saturday by Chief Justice John Roberts and the man he will replace, the Court's crucial swing vote, Anthony Kennedy.Democrats furiously accused the GOP of short-circuiting efforts to examine Ford's allegations and of rushing the nomination through while ignoring the changed political dynamics surrounding complaints of misconduct against powerful men ushered in by the #MeToo movement.Senate Minority Leader Chuck Schumer called the nomination "one of the saddest moments in the history of the Senate," and said, "this chapter will be a flashing red warning light of what to avoid."Republicans "conducted one of the least transparent, least fair, most biased processes in Senate history, slanting the table from the very beginning to produce their desired result," he added.Majority Leader Mitch McConnell described Kavanaugh as a "superstar."McConnell, who stalled Barack Obama's nomination of Merrick Garland to the court in his final year in office and for whom the new conservative majority represents a defining achievement, predicted that Democratic tactics during confirmation battle would electrify Republican voters in November."They managed to deliver the only thing we had not been able to figure out how to do, which is to get our folks fired up," McConnell said. "The other side is obviously fired up, they have been all year."Kavanaugh's confirmation leaves the Senate traumatized with Republicans and Democrats as estranged as at any time in recent memory, reflecting the cavernous divides in the country itself during a presidency that has ignited rare political passions.It represents the culmination of a decades-long project by the conservative movement to construct a like-minded majority on the Supreme Court which has been a defining and unifying cause in successive congressional and presidential campaigns.The new profile of the court immediately makes Trump a consequential president, for all of the chaos and discord that rages around his White House, and means his legacy will include an achievement that eluded previous Republican presidents -- all of whom had more authentic conservative credentials.The ferocious nature of the confirmation battle could also have an impact on the Court itself, as Kavanaugh's vehement and politicized defense of his own behavior raised questions about his temperament and whether he could genuinely be an honest broker and implementer of the law in the most sensitive cases. 4844

The Saharan Air Layer remains quite active as dust continues to stream west off the African coast. The initial plume is currently over much of the Southeast US with another large plume approaching the Caribbean. Here is the latest (Fri June 26) 10 day computer model dust forecast pic.twitter.com/0KUxLkOkjA— NWS Eastern Region (@NWSEastern) June 26, 2020 363

The Trump campaign has officially requested a recount in two Wisconsin counties, just one day after all 72 counties had reported they finished their canvassing.President Donald Trump and his campaign had a deadline of 5 p.m. Wednesday to demand a recount in the state.The Wisconsin Election Commission (WEC) said the request could be delivered to the commission in person or filed electronically, as long as it was received by 5 p.m.On Wednesday, the Trump campaign ordered a recount in both Milwaukee and Dane Counties — two of the most populous and Democratic-leaning counties in the state.The WEC added that the campaign wired million Tuesday evening.The fees for a recount vary based on where the president would like a recount. The whole state is much more expensive than a county by county recount.The news of the recount comes after The Associated Press projected Joe Biden as the winner in Wisconsin. Biden leads Trump statewide by about 0.3%, or 20,000 votes.This story was originally published by Julia Marshall on WTMJ in Milwaukee, Wisconsin. 1065

The White House physician assigned to Vice President Mike Pence, Jennifer Pena, has resigned, his office told CNN in a statement Friday. Pena worked in the White House medical unit."The vice president's office was informed today by the White House Medical Unit of the resignation. Physicians assigned to the vice president report to the White House Medical Unit and thus any resignation would go entirely through the Medical Unit, not the vice president's office," Alyssa Farah, Pence's press secretary, said in a statement to CNN.This comes after CNN reported Tuesday that a Pence doctor privately raised alarms within the White House last fall that President Donald Trump's doctor Ronny Jackson may have violated federal privacy protections for a key patient -- Pence's wife, Karen -- and intimidated the vice president's doctor during angry confrontations over the episode.  890

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274